Deep Tech Startups

Cambrian Vision augments industrial robot arms with computer vision and AI-powered perception capabilities for tasks like bin picking, assembly, and cable handling. The platform includes synthetic data generation, path planning, simulation, and APIs for integration with major robot brands.

3 investors

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria. Its pipeline includes a first-in-class mitophagy agonist intended for therapeutic use in aging- and disease-related conditions.

3 investors

Capture6 develops modular technology that treats salt water and brine to recover freshwater while capturing and storing CO₂, producing byproducts such as freshwater and green chemicals. It partners with industries, governments, and communities to provide water security and durable carbon removal.

3 investors

Carthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.

3 investors

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications. The company combines molecular biology expertise with a proprietary discovery platform to identify and eliminate disease-causing cellular elements.

3 investors

Catalyx builds standardized infrastructure for deploying sensor payloads into orbit, offering common power, thermal, and data interfaces along with continuous monitoring and real-time data transmission. The product targets space operators seeking faster, lower-cost payload deployment.

3 investors

Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.

3 investors

Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.

3 investors

Celerity Craft is developing the Dynamic Air Cushion Vehicle (DACV), a three-hulled marine vessel technology that lifts the craft on an energized column of air to reduce drag, enabling faster, zero-emission electric travel. It targets commercial, military, and recreational marine sectors, including high-use ferry routes.

3 investors

Cella accelerates the natural geologic process that turns carbon dioxide into a mineral by injecting captured atmospheric CO2 into volcanic rock, where mineralization permanently stores it underground. The company provides carbon storage technology designed to scale alongside carbon capture across varied geologic settings.

3 investors

Cellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers. The company serves patients with challenging diseases through AI-driven drug discovery.

3 investors

CellCo applies computational simulation, generative AI, and medicinal chemistry to design glycan-enabled therapeutics, engineering glycan ligands that direct RNA, small molecules, and antibodies to specific tissues and cell types. It develops platforms for molecular dynamics, synthetic data generation, and foundation models targeting glycan chemistry, immune modulation, and targeted drug delivery.

3 investors

CellDom develops CloneXplorer, a live single-cell assay platform combining functional imaging, molecular readouts, and integrated cell retrieval for high-resolution cell analysis. The platform enables CAR T-cell potency testing, antibody/TCR discovery, cell line development, and precision medicine applications for research and therapeutic development teams.

3 investors

Cellivate develops animal-free cell growth solutions for cell culture and biomanufacturing, offering an extracellular vesicle (EV)-based alternative to Fetal Bovine Serum (FBS). Its products target academic, industrial, and clinical labs performing advanced cell culture and biomanufacturing.

3 investors

Cellply develops VivaCyte, an automated platform that combines microfluidic consumables, an instrument, and image-analysis software to characterize cell therapies at single-cell resolution. It serves cell therapy discovery and development teams, measuring phenotype and function across thousands of single-cell co-cultures and comparing up to 128 conditions per run.

3 investors

Cellsonics provides cell dissociation technology for research scientists using acoustic waveforms to isolate cells from tissue with higher biological relevance than conventional methods.

3 investors

Centerline Biomedical develops IOPS®, a 510(k)-cleared endovascular navigation technology that provides real-time 3D image guidance for physicians performing catheterization and other endovascular procedures. The technology is designed to reduce radiation exposure and improve procedural accuracy for interventional cardiologists, vascular surgeons, and other interventionalists.

3 investors

CESS is a decentralized storage infrastructure network that pools storage resources and provides data economy services, combining distributed storage and content delivery with cryptographic security mechanisms.

3 investors

Chakra Labs develops high-fidelity simulation environments and research infrastructure for training and evaluating frontier AI models on computer use tasks. The platform provides containerized reinforcement learning environments designed for autonomous agent research, with support for both GUI and programmatic interactions.

3 investors

Chasm builds a decentralized protocol for creating, deploying, and monetizing AI agents by combining artificial intelligence with blockchain technology. Its Chasm Protocol is designed to coordinate resource management and interactions among AI agents in a decentralized network.

3 investors

Hydrogen Labs develops cryptocurrency financial infrastructure, specifically liquid staking token technology and distributed validator solutions that enable crypto asset holders to optimize returns and reduce risks on blockchain networks.

3 investors

ChemT builds CelMo, an AI-driven virtual cell platform that models cell states and predicts responses to process, genetic, and molecular changes to optimize biomanufacturing. It applies this to CHO cells for antibody/protein production and T cell therapy manufacturing (including its Chemplify small molecule), serving biopharma teams working on cell line and process development.

3 investors

Chipiron develops a low-field MRI system using a patented cryogenic ultrasensitive detection system and AI-based noise cancellation and image reconstruction, aiming to acquire MRI signals in open environments without a Faraday cage. Its technology includes a breast-dedicated imaging sequence designed for clinically relevant scan times.

3 investors

Chirp Token develops network infrastructure for decentralized connectivity and IoT applications. The company focuses on building foundational technology to enable the vision of widespread interconnected systems.

3 investors